FDA EXTENDS PDUFA DATE OF BIOHAVEN'S TRORILUZOLE NDA FOR RARE DISEASE SPINOCEREBELLAR ATAXIA
BIOHAVEN LTD - FDA'S DECISION REGARDING NDA IS NOW EXPECTED IN 4Q 2025.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.